Navigation Links
Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease
Date:12/9/2009

PROVIDENCE, R.I., Dec. 9 /PRNewswire/ -- The results of a new study on immune-based treatment of Alzheimer's disease (AD), which was conducted at 30 sites around the country, will be published in the December 15 issue of Neurology®. Lead author, Stephen P. Salloway, MD, MS, director of the Butler Hospital Memory and Aging Program and a professor of neurology and psychiatry at the Warren Alpert Medical School of Brown University, says that this 18-month phase two study on slowing the disease process in Alzheimer's patients offers promising results. The study tested the effectiveness of bapineuzumab, which acts like a vaccine to reduce the levels of toxic amyloid protein thought to play a key role in causing Alzheimer's.

"This study was built from the lab up," says Salloway. While many treatments for Alzheimer's disease have been discovered by observing the impact of treatments for other conditions, this treatment is among the first to use what scientists have developed in the lab to treat the underlying cause of the disease. "This study offers a real step forward in our development of effective treatments for Alzheimer's disease," says Salloway.

The results of the study offer an important piece of the Alzheimer's puzzle. What Dr. Salloway and his colleagues found was that the success of this treatment may be influenced by the patient's genetic makeup. Some people have a genetic marker, called the ApoE e4 gene, which makes them more likely to develop Alzheimer's. This gene increases risk and makes it more likely for people to develop the disease at an earlier age. In this study, people who didn't have the gene responded more positively to the treatment.

Sponsored by Elan Pharmaceuticals and Wyeth Research, the study helped to shape a phase three trial that is now in progress. Based on the results of Salloway's phase two trial, the new study will track patients with the ApoE e4 gene separately from those who do not carry the gene, further advancing research on the effectiveness of bapineuzumab.

Affiliated with Brown University's Warren Alpert Medical School's Department of Psychiatry, Butler Hospital is a major research, treatment, and teaching center. For more details on the study results visit neurology.org. More information about Butler Hospital's Alzheimer's and other memory disorders research call 401-455-6265, or visit butler.org.

SOURCE Butler Hospital


'/>"/>
SOURCE Butler Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. George Butler Joins Bionovos Board of Directors
2. Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
3. Xceleron Names Michael Butler as President & CEO
4. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Florida Childrens Hospital and Disney Unite to Create Magical Pediatric Hospital
7. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
8. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
9. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
10. Candid Details on Hospitals Quality of Care Are Now at Your Fingertips - Just Like It Should Be
11. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):